CN Patent

CN1443195A — 新型lhrh拮抗剂,其制备方法和药物用途

Assigned to Aeterna Zentaris GmbH · Expires 2003-09-17 · 23y expired

What this patent protects

本发明涉及包含N－甲基化的氨基酸组分以及水溶性改善的肽。根据本发明，含有所述肽的药物可用于治疗激素－依赖性肿瘤和受激素影响的非恶性疾病状态。

USPTO Abstract

本发明涉及包含N－甲基化的氨基酸组分以及水溶性改善的肽。根据本发明，含有所述肽的药物可用于治疗激素－依赖性肿瘤和受激素影响的非恶性疾病状态。

Drugs covered by this patent

degarelix-acetate (DEGARELIX ACETATE)

Patent Metadata

Patent number: CN1443195A
Jurisdiction: CN
Classification: —
Expires: 2003-09-17
Drug substance claim: No
Drug product claim: No
Assignee: Aeterna Zentaris GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.